Seattle Genetics Inc. (NASDAQ:SGEN) shares traded up 2.2% on Tuesday . The company traded as high as $55.73 and last traded at $55.25, with a volume of 362,715 shares trading hands. The stock had previously closed at $54.08.

A number of research analysts have weighed in on the company. Leerink Swann restated a “buy” rating and issued a $62.00 price target on shares of Seattle Genetics in a research note on Friday. Goldman Sachs Group Inc. downgraded Seattle Genetics from a “neutral” rating to a “sell” rating in a research note on Friday. Morgan Stanley began coverage on Seattle Genetics in a research note on Wednesday, September 7th. They set an “overweight” rating and a $60.00 target price for the company. RBC Capital Markets reiterated an “outperform” rating on shares of Seattle Genetics in a research note on Wednesday, July 27th. Finally, Barclays PLC lifted their target price on Seattle Genetics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $49.92.

The stock’s 50 day moving average is $47.83 and its 200-day moving average is $40.66. The stock’s market capitalization is $7.70 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/seattle-genetics-inc-sgen-trading-2-2-higher.html

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Tuesday, July 26th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. Seattle Genetics had a negative return on equity of 15.29% and a negative net margin of 27.21%. The business had revenue of $95.40 million for the quarter, compared to the consensus estimate of $94.56 million. During the same period in the prior year, the business earned ($0.38) EPS. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. Analysts predict that Seattle Genetics Inc. will post ($1.00) earnings per share for the current fiscal year.

In other news, insider Clay B. Siegall sold 4,042 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $45.20, for a total value of $182,698.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eric Dobmeier sold 22,918 shares of the stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $54.04, for a total value of $1,238,488.72. The disclosure for this sale can be found here. Corporate insiders own 33.30% of the company’s stock.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Seattle Genetics by 37.5% in the second quarter. JPMorgan Chase & Co. now owns 3,595 shares of the company’s stock valued at $145,000 after buying an additional 981 shares during the period. HighTower Advisors LLC bought a new stake in shares of Seattle Genetics during the second quarter valued at approximately $206,000. Carl Domino Inc bought a new stake in shares of Seattle Genetics during the second quarter valued at approximately $218,000. Levin Capital Strategies L.P. bought a new stake in shares of Seattle Genetics during the second quarter valued at approximately $218,000. Finally, Capstone Asset Management Co. bought a new stake in shares of Seattle Genetics during the second quarter valued at approximately $222,000. 97.93% of the stock is owned by hedge funds and other institutional investors.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.